Meeting
2019 ASCO Annual Meeting
A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.
Authors
Marco Montillo
Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
Marco Montillo , Davide Rossi , Emanuele Zucca , Anna Maria Frustaci , Stefano Pileri , Franco Cavalli , Alessandra Tedeschi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
2018-005028-40
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7575)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7575
Abstract #
TPS7575
Poster Bd #
324b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
First Author: Philippe Armand
Poster
2022 ASCO Annual Meeting
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
First Author: Naoki Furuya
Poster
2021 ASCO Annual Meeting
Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.
First Author: Takefumi Komiya
Poster
2017 ASCO Annual Meeting
DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab).
First Author: Steven H. Lin